In the above-named article by Miller BS, Velazquez E, and Yuen KCJ (J Clin Endo Metab. 2019; 105(6): e2121–e2133; doi: 10.1210/clinem/dgz149) there was a transcription error in Table 1 as published:
In Table 1, Page 5, 5th column, 8th row, the company “Alteogen” under the “Current Status” column was incorrectly described as “Bankrupt in 2009, stopped phase 2 study in CGHD.” This statement is incorrect as the company Alteogen remains a currently viable bio-tech company globally. The statement should have been “Phase 1 study completed” in the “Current Status” column and “Phase 2 study in AGHD ongoing” in the “Ongoing Research” column.
The content “Bankrupt in 2009, stopped phase 2 study in CGHD” was intended to be attributed to Altus Pharmaceuticals in Table 1, Page 4, 5th column, 2nd row. The modified Table 1 includes the updated statement “Bankrupt in 2009, stopped phase 2 study in CGHD, Althea acquired assets in 2010.”
This modifications to Table 1 do not change the scientific conclusions of the article in any way.
The table has been corrected online.
doi: 10.1210/clinem/dgz149